BioSpace News Archive

Sentynl acquires CUTX-101, Copper Histidinate, for $20 million in upfront and regulatory milestone payments through NDA approval, as well as potential sales milestones plus royalties Cyprium will retain 100% ownership over any FDA priority review voucher that may be issued at NDA approval for CUTX-101 Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the third quarter of 2021 and to be completed during the fourth quarter of 2021

Academia-Industry Partnership to Support Improvements in UST Applications and Allow Global Food Companies Access to UST for Preparation of Safer, More Nutritious Liquid Foods and Beverages [24-February-2021] SOUTH EASTON, Mass. , Feb. 24, 2021 /PRNewswire/ --Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broa

Seven Bridges, the industry-leading bioinformatics ecosystem provider, is supporting Pfizer Inc. (NYSE: PFE) in the development of a data management and collaboration solution for the biopharmaceutical company’s single-cell ribonucleic acid (RNA) sequencing (scRNASeq) data

Vertice Pharma (“Vertice”), a specialty pharmaceuticals company focused on improving patients’ health, today announced the launch of THYQUIDITY.

Amyris, Inc. announced that its Pipette® clean baby care brand will expand its brick and mortar retail presence in more than 600 Target stores across North America beginning in March 2021.

The FDA-authorized, saliva-based COVID-19 RT-PCR test expands testing access with a comfortable, at-home alternative - eliminating in-person waits and reducing exposure risk

Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to the company’s GI Bleed Risk Alert System (Gibras).

Seagen to Present at the Cowen 41 st Annual Healthcare Conference

- Phil Greenberg, M.D., Aude Chapuis, M.D., and Tom Schmitt, Ph.D. join as advisors to help guide the company’s immunological cell therapy research efforts -

Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer will present at three upcoming investor conferences in March: Cowen 41 st Annual Healthcare Conference :